NCT04424654View on ClinicalTrials.gov

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

May 1, 2022

Study Completion Date

July 1, 2022

Conditions
Prostate Cancer
Interventions
DRUG

Testosterone cypionate

Testosterone cypionate 400 mg IM

Trial Locations (2)

90035-000

Hospital Moinhos de Vento, Porto Alegre

01308050

Hospital Sirio-Libanes, São Paulo

All Listed Sponsors
collaborator

Hospital Moinhos de Vento

OTHER

lead

Hospital Sirio-Libanes

OTHER

NCT04424654 - Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy | Biotech Hunter | Biotech Hunter